Word: drugging
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...doesn't have to be this way. TB is an entirely preventable and treatable disease. And the drug-resistant strains beginning to emerge in Africa, Russia, China and India, say experts, are epidemics of our own making. Unlike HIV, the tubercle bacillus succumbs to powerful medications. But these drugs are not where they need to be, and when they are, spotty monitoring and poor health infrastructure make it hard to ensure that patients take their daily doses for the six months that are needed to eradicate the infection--all of which encourages drug-resistant strains to survive and keep...
...nondescript building in Nutley, N.J., nearly 1 million tiny glass plates most likely hold the future of Swiss pharmaceutical giant Roche. On each sits one of some 920,000 drug compounds Roche owns, which the researchers at its U.S. headquarters spend their day mixing and matching in the hope of finding the next cure for diabetes, rheumatoid arthritis or even cancer. Until now, however, 9 out of 10 times these searches have yielded only dead ends...
...year. Its total sales reached $43 billion, generating profits of $10.5 billion. Nonetheless, the days of this trial-and-error approach may soon be over. All of Big Pharma is feeling pressure--from Wall Street, regulators and customers--to take a smarter path to discovery for that next blockbuster drug. And who wins vs. who is left behind is still very much...
Meanwhile, not only are regulators scrutinizing steep pricing models, but in this post-Vioxx era, agencies like the U.S. Food and Drug Administration (FDA) are also requiring more and more testing. That has led many firms to consult regulators much earlier in the R&D process. "You must align expectations as early as you can with the FDA," Roche CEO Severin Schwan says. "It leads to a much more efficient, effective use of resources on both sides...
...demand for cancer drugs, for one, will grow exponentially with this treatment approach. But more important, Roche can now use biomarkers to determine much earlier in the R&D process whether a drug will pan out. Down the pipeline, diagnostics identify which patients most benefit from a therapy, giving clinical trials tailored to that subset a better chance of succeeding. Moreover, any patient for whom the drug wouldn't work or whom the drug could harm can be excluded...